Charles River Laboratories International (NYSE:CRL) Price Target Lowered to $166.00 at Barclays

Charles River Laboratories International (NYSE:CRL) had its price target decreased by stock analysts at Barclays from $205.00 to $166.00 in a report released on Tuesday,Benzinga reports. The firm presently has an “equal weight” rating on the medical research company’s stock. Barclays‘s target price would suggest a potential upside of 9.16% from the stock’s current price.

Several other research analysts also recently issued reports on CRL. Bank of America lowered their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Morgan Stanley decreased their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. TD Cowen upped their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Finally, UBS Group reaffirmed a “neutral” rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $197.64.

Charles River Laboratories International Stock Down 0.7 %

Shares of NYSE:CRL opened at $152.07 on Tuesday. Charles River Laboratories International has a 52-week low of $150.79 and a 52-week high of $275.00. The company has a fifty day moving average of $175.44 and a 200-day moving average of $189.72. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The company has a market capitalization of $7.78 billion, a PE ratio of 19.03, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Charles River Laboratories International by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 298,250 shares of the medical research company’s stock valued at $55,057,000 after acquiring an additional 46,994 shares in the last quarter. Voloridge Investment Management LLC lifted its position in shares of Charles River Laboratories International by 107.0% during the fourth quarter. Voloridge Investment Management LLC now owns 156,574 shares of the medical research company’s stock valued at $28,904,000 after purchasing an additional 80,918 shares in the last quarter. Worldquant Millennium Advisors LLC bought a new position in shares of Charles River Laboratories International during the fourth quarter valued at about $24,446,000. Twinbeech Capital LP lifted its position in shares of Charles River Laboratories International by 1,584.8% during the 4th quarter. Twinbeech Capital LP now owns 44,480 shares of the medical research company’s stock worth $8,211,000 after buying an additional 41,840 shares in the last quarter. Finally, Two Sigma Advisers LP raised its stake in shares of Charles River Laboratories International by 72.4% during the 4th quarter. Two Sigma Advisers LP now owns 28,100 shares of the medical research company’s stock worth $5,187,000 after purchasing an additional 11,800 shares during the period. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).